Aquestive Therapeutics Inc (NASDAQ:AQST)’s Trend Unknown, Especially After Increased Shorts

September 16, 2018 - By James Guidry

The stock of Aquestive Therapeutics Inc (NASDAQ:AQST) registered an increase of 153.85% in short interest. AQST’s total short interest was 16,500 shares in September as published by FINRA. Its up 153.85% from 6,500 shares, reported previously. With 126,900 shares average volume, it will take short sellers 0 days to cover their AQST’s short positions. The short interest to Aquestive Therapeutics Inc’s float is 0.14%.

The stock decreased 9.78% or $1.79 during the last trading session, reaching $16.52. About 176,741 shares traded. Aquestive Therapeutics, Inc. (NASDAQ:AQST) has 0.00% since September 16, 2017 and is . It has underperformed by 15.62% the S&P500.

Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company has market cap of $412.04 million. The Company’s products are developed using its PharmFilm technology. It currently has negative earnings. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

More notable recent Aquestive Therapeutics, Inc. (NASDAQ:AQST) news were published by: Benzinga.com which released: “Benzinga’s Top Upgrades, Downgrades For September 13, 2018” on September 13, 2018, also Livetradingnews.com with their article: “The Street’s Key Stock Analysts Research Reports” published on September 14, 2018, Seekingalpha.com published: “Aquestive Therapeutics adds to rally, up 7%” on September 13, 2018. More interesting news about Aquestive Therapeutics, Inc. (NASDAQ:AQST) were released by: 247Wallst.com and their article: “Top Analyst Upgrades and Downgrades: American Superconductor, Galapagos, Humana, Intel, Philips, Pinduoduo …” published on September 13, 2018 as well as Seekingalpha.com‘s news article titled: “More on Aquestive Therapeutics Q2 results” with publication date: September 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.